Orientin Reduces the Effects of Repeated Procedural Neonatal Pain in Adulthood: Network Pharmacology Analysis, Molecular Docking Analysis, and Experimental Validation

Guo, Dong-Dong; Huang, Hai-Yan; Liu, Hai-E.; Liu, Kun; Luo, Xing-Jing

doi:https://doi.org/10.1155/2023/8893932

Pain Research and Management

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusion Data Availability Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2023 | Article ID 8893932 | https://doi.org/10.1155/2023/8893932

Orientin Reduces the Effects of Repeated Procedural Neonatal Pain in Adulthood: Network Pharmacology Analysis, Molecular Docking Analysis, and Experimental Validation

Dong-Dong Guo,¹Hai-Yan Huang,²Hai-E. Liu,¹Kun Liu,¹and Xing-Jing Luo¹

Academic Editor: Alessandro Vittori

Received20 Feb 2023

Revised08 May 2023

Accepted08 Nov 2023

Published24 Nov 2023

Abstract

Background. Premature infants often undergo painful procedures and consequently experience repeated procedural neonatal pain. This can elicit hyperalgesia and cognitive impairment in adulthood. Treatments for neonatal pain are limited. Orientin is a flavonoid C-glycoside that has repeatedly been shown to have pharmacological effects in the past decades. The aim of this study was to systematically explore the effect of orientin on repeated procedural neonatal pain using network pharmacology, molecular docking analysis, and experimental validation. Methods. Several compound-protein databases and disease-protein databases were employed to identify proteins that were both predicted targets of orientin and involved in neonatal pain. A protein-protein interaction (PPI) network was constructed, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to explore the potential mechanism of action. Molecular docking analysis was employed to calculate the binding energy and visualize the interactions between orientin and potential target proteins. Finally, a mouse model of repeated procedural neonatal pain was established and orientin was administered for 6 days. The mechanical and thermal pain thresholds were assessed in neonates and adult mice. A Morris water maze was employed to investigate cognitive impairment in adult mice. Results. A total of 286 proteins that were both predicted targets of orientin and involved in neonatal pain were identified. The hub proteins were SRC, HSP90AA1, MAPK1, RHOA, EGFR, AKT1, PTPN11, ESR1, RXRA, and HRAS. GO analysis indicated that the primary biological process (BP), molecular function (MF), and cellular component (CC) were protein phosphorylation, protein kinase activity, and vesicle lumen, respectively. KEGG analysis revealed that the mitogen-activated protein kinase (MAPK) signaling pathway may be the key to the mechanism of action. Molecular docking analysis showed the high binding affinities of orientin for MAPK1, MAPK8, and MAPK14. In mice, orientin inhibited the hyperalgesia in the pain threshold tests in neonates and adult mice and cognitive impairment in adult mice. Immunofluorescence showed that phosphorylated MAPK1 (p-ERK) protein levels in the hippocampus and spinal dorsal horn were downregulated by orientin. Conclusion. The findings suggested that orientin alleviates neonatal pain, and the MAPK signaling pathway is involved.

1. Introduction

The vital signs of premature infants (born before 37 weeks of pregnancy) are often poor worrying, so they require a neonatal intensive care unit stay (mean duration: 25 days) and 10–18 painful procedures every day according to reports in the literature [1–3]. Neonates can feel pain, and the pain may elicit several immediate and long-term neurobehavioral abnormalities, including changes in pain perception and cognitive impairments in adulthood [4–6]. Treatments in clinical practice for repeated procedural neonatal pain are opioid and nonopioid analgesics (acetaminophen and nonsteroidal inflammatory drugs), but all abovementioned drugs must be carefully administered due to underdeveloped renal function in newborn [7] and few reported further changes in adulthood. Are there any drugs that can improve immediate and long-term neurobehavioral abnormalities induced by neonatal pain? Ranger et al. reported a failed attempt at using sucrose in a mouse model of repeated procedural neonatal pain [8]. Paracetamol only inhibited long-term behavioral effects, but not repeated procedural neonatal pain [9].

Orientin is a water-soluble flavonoid C-glycoside [10] that belongs to the family of flavonoid glycosides [11]. Orientin widely existed in plants worldwide, for example, bamboo [12], Celtis africana [13], and Jatropha gossypifolia [14]. In the past decades, it has been shown to have multiple pharmacological effects, such as anticancer [15], antiviral and antibacterial [16], antioxidant [17], and anti-inflammatory [18] effects. Due to its anti-inflammatory and antioxidant effects, it exerts many protective effects, including protection against myocardial infarction [19], radioprotection [20], neuroprotection [21], attenuation of cerebral ischemia/reperfusion injury [22], and inhibition of high-glucose-induced apoptosis involving mitophagy [23]. We previously revealed the analgesic effect of orientin in neuropathic pain [24]. Although it is a widely-recognized low-toxic [10], water-soluble flavonoid, whether it can treat neonatal pain is unknown.

Unlike previous predictions of the mechanisms of action of drugs, which relied on experiments, network pharmacology analysis to predict mechanisms does not require experimentation, and this field has been developing rapidly, especially in the natural product field [25]. Network pharmacology is based on systems biology and bioinformatics and can involve high-throughput screening and the construction of multimolecular, multitarget, and multilink “drug-compound-target” network models, which reveal multilevel information [26]. Furthermore, molecular docking analysis (based on artificial intelligence software) can be used to indicate possible interactions between a compound and its target proteins, the possible amino acid sequence length, and types of binding amino acids [27]. This study aimed to systematically explore the effect of orientin on repeated procedural neonatal pain using network pharmacology analysis, molecular docking analysis, and experimental validation. Target proteins of orientin that are involved in neonatal pain were used in a protein-protein interaction (PPI) network and the key proteins were then identified. A key signaling pathway involved in the mechanism of action was predicted, and the predicted mechanism was validated in vivo.

2. Materials and Methods

2.1. Prediction of Target Proteins

The network pharmacology analysis was performed following previous reports [28, 29]. The target proteins of orientin were predicted by using The Chinese Traditional Medicine System Pharmacological Database and Analysis Platform (TCMSP) [30], SwissTargetPrediction database [31], and SuperPred database [32] by using the term “orientin.” The target proteins involved in neonatal pain were obtained using the GeneCards database [33], DisGeNEt database [34], and DrugBank database [35] using the term “neonatal pain.” Duplicates were removed and the canonical protein names were determined using the UniProt database [36] and then inputted into Venny 2.1.0 [37] to identify the overlapping proteins and to create a Venn diagram.

2.2. Protein-Protein Interaction (PPI) Network

The overlapping proteins were submitted to the STRING database [38] to create a PPI network and to detect the links and control hubs. The species was limited to “Homo sapiens” and the minimum required interaction score was set at >0.7 (high confidence) [39]. The PPIs were downloaded into Cytoscape software v3.8.2 [40], which is commonly used for visualization in complex networks. The cytoHubba plugin [41] was used to determine the top 10 hub proteins based on degree.

2.3. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) Enrichment Analyses

Metascape [42], an automatic bioinformatics tool, was used to subject the overlapping proteins to a GO analysis of enriched gene functions, involving molecular functions (MFs), biological processes (BPs), and cellular components (CCs). A KEGG analysis was also performed; the results were downloaded and the top 20 pathways were automatically visualized using Metascape.

2.4. Molecular Docking Analysis

To further validate the network pharmacology results, which predicted protein targets of orientin to treat neonatal pain, a molecular docking analysis of orientin and key target proteins was performed. In brief, a 2D structure of orientin was downloaded from the PubChem database and converted to a 3D structure using ChemBio3D mol2 software after minimizing the energy. The 3D structures of the target proteins were downloaded from the Protein Data Bank (PDB) and any ligands were removed. AutoDock v1.5.7 was employed for ligand preparation, water removal, nonpolar hydrogen atom preparation, and locating the active pocket. AutoDock Vina [43] was used to determine the final docking conformation. The binding amino acids in the proteins and the conformation with the best binding affinity were visualized using PyMOL Molecular Graphics System v2.0 (Schrödinger, LLC, Germany) [44] in the Python environment.

2.5. Animal Grouping and Model Establishment

Ethics approval (grant no. 2022007) was obtained from the Laboratory Animal Ethics Committee of the Shanghai Municipal Hospital of Traditional Chinese Medicine of the Shanghai University of Traditional Chinese Medicine. Institute of Cancer Research (ICR) mice were provided by Shanghai Jie-si-jie laboratory Animal Co. Ltd (Shanghai Lab Animal grant no. SCXK (H) 2018-0004).

A review concerning children born prematurely who are subjected to neonatal repeated procedural pain is linked to changes in cognitive, pain threshold and psychosocial function such as vulnerability to stress disorders in adulthood life [45]. To mimic NICU pain in a preterm neonate due to repeated procedures, a repetitive needle-pricking rat model was employed in 2012 [46]. Pups in the model group received needle prick several times while pups in the tactile control group received gentle tactile stimulations. After that, this model was widely used for the evaluation of the effectiveness of drugs and interventions [8, 47]. In this study, a model of repeated procedural neonatal pain was established by mainly following the method reported by Ranger et al. [8]. After obtaining pregnant mice and after delivery of the pups, 1-day-old pups (P1) were randomly assigned to six groups (n = 6 per group): (1) control group (no stimulation or treatment), (2) model group (a needle was used to prick a hind paw, and sterile water was administered orally (Figure 1(a))), (3) sham group (a cotton-tipped swab was applied to a hind paw to create tactile pressure (Figure 1(b))), and (4–6) three orientin groups (stimulus same with the model group, and oral orientin at 7, 14, or 21 mg/kg was administered (Figure 1(c))). The stimuli and orientin were administered from P1 to P6. The stimuli were administered 10 times per day, while orientin was administered 4 times per day (AM 8, AM 12, PM 4, and PM 8). After P6, there were no orientin administrations.

(a)

(b)

(c)

(d)

Some studies added a reinjury at 8 weeks to observe changes in pain threshold during adulthood because neonatal repeated procedural pain leads not only to acute short-term hyperalgesia but also to changes in pain threshold in adulthood [9, 48]. In this study, a reinjury was also established following previously described methods [9, 48]. In brief, at week 8 (W8), for each relevant mouse, a hind paw was pricked with a needle. No drug was administered this time. The flowchart is shown in Figure 1(d).

2.6. Paw Mechanical Withdrawal Threshold (PWMT) and Thermal Withdrawal Latency (TWL)

PWMT was assessed using calibrated von Frey filaments (Stoelting, Kiel, WI, USA) at P7 and W8. The mice were placed on a metal mesh floor in a chamber. After accommodation, a von Frey filament (0.04, 0.07, 0.16, 0.4, 0.6, 1.0, and 1.4 g) was pressed perpendicular to the plantar surface of the hind paw until it bent [49]. The minimum force required to induce three positive withdrawal responses (withdrawal or contraction) in five attempts using the von Frey filament (with an interval >1 min) was recorded [50]. If the maximum stimulation intensity (1.4 g) did not produce a withdrawal response, the force was recorded as 1.4 g. Tests were conducted three times (with a minimum interval of 1 h), and the mean force was recorded as PWMT.

TWL was assessed at P7 and W8. The mice were placed on a hot plate at 52.5°C (IITC Life Science, Woodland Hills, CA, USA) [50]. The response latency to elicit a positive withdrawal response (e.g., withdrawal, licking, retraction, or jumping) was recorded. If a positive response was not elicited, the mice stayed on the hot plate for 30 s at most (to avoid scalding and injury) and the TWL was recorded as 30 s. Tests were conducted three times (with a minimum interval of 1 h), and the mean value was recorded as TWL.

2.7. Morris Water Maze (MWM) Test

The MWM test was employed to investigate the effect of orientin on hippocampal-dependent spatial reference memory in adult mice at W8 [51]. The test was performed using a video analysis system (XR-XM-101, XinRuan Corporation, Shanghai, China), a round gray water pool (height: 1.2 m, weight: 0.5 m; divided into four quadrants according to the four directions of northeast, southeast, southwest, and northwest), a small underwater platform (height: 29 cm), and a tracking camera positioned directly over the pool. To ensure accommodation, the mice were allowed to swim freely for 2 min without the platform in the pool on the day before the experiment. The MWM experiment is composed of two tests: (1) spatial learning test (lasting 5 days) in which each mouse was put into the pool every day and the time required for the mouse to find the platform was recorded as the latency (in seconds; if the mouse could not find the platform within 120 s, it was placed on the platform for 30 s) and (2) probe test (on day 6) in which each mouse was placed at a specific location in the pool (with the platform removed) and the movement of the mouse was recorded and analyzed.

2.8. RT-PCR

The total RNA was isolated from the brain using Trizol, and the ratio of A260/A280 values was employed to quantify the concentration of RNA. cDNA synthesis and quantitative PCR were performed following a previous report [52]. The GAPDH was employed as a housekeeper gene, and the relative expression levels of MAPK1 and GAPDH genes were calculated by the 2^−△△ct method. Target primer sequences of MAPK1 were provided by Vazyme (Vazyme, Nanjing, China) as follows (5′–3′): MAPK1 (GCACCAACCATCGAGCAAAT and CTTGAGGTCACGGTGCAGAA).

2.9. Immunofluorescence

Immunofluorescence experiments were employed to investigate the protein level of phosphorylated mitogen-activated protein kinase 1 (pMAPK1) in the hippocampus and spinal dorsal horn of the mice following a previously described method [53]. After the behavioral tests, the mice were anaesthetized with an intraperitoneal injection of 1% sodium pentobarbital (50 mg/kg) and then perfused with saline and 4% paraformaldehyde. After that, the brain and spine were carefully harvested and frozen in liquid nitrogen. Hippocampus and spinal dorsal horn samples were cut into 4-μm sections, permeabilized with 0.2% Triton X-100 in phosphate-buffered saline, and blocked using a blocking buffer. A primary antibody against pMAPK1 (p-ERK) (ab201015, 1 : 200; Abcam, Cambridge, UK) was added and the sections were incubated overnight at 4°C followed by incubation with an Alexa Fluor® 555-conjugated secondary antibody. Images were then captured using an immunofluorescent camera (3DHISTECH Ltd., Budapest, Hungary). The cornu ammonis 1 and 3 (CA1 and CA3) regions in the hippocampus were determined following a previously described method [54]. The relative fluorescence density of the target protein within a fixed area was determined using Image-Pro Plus v6.0.

2.10. Statistical Analysis

The network pharmacology and molecular docking data were generated by software or databases as mentioned above. The experimental data were expressed as mean ± SD if not otherwise stated. The statistical analysis was performed in SPSS v27 first with an orthogonality test and homogeneity test of variance, followed by the one-way analysis of variance (ANOVA) and the least significant difference (LSD) or Tukey’s post hoc test (n = 6). was considered significant. The results were visualized using GraphPad Prism v6.

3. Results

3.1. Prediction of Target Proteins

After removing the duplicates, 417 predicted targets of orientin were obtained from the abovementioned databases. In addition, 6322 target proteins involved in neonatal pain were obtained from the abovementioned databases. The 286 overlapping targets are shown in a Venn diagram in Figure 2(a).

(a)

(b)

3.2. PPI Network

The STRING database was used to construct a PPI network of the 286 proteins. As shown in Figure 2(b), there were 286 nodes and 762 edges, with a mean node degree of 5.08. The proteins were grouped into one cluster, with a few independent, unrelated proteins. There were many interactions among the proteins in the cluster, and the principal proteins were CDK4, MAPK14, and MAPK1. The cytoHubba plugin in Cytoscape was used to determine the following top 15 hub proteins (ranked by degree) in the PPI network: SRC (with a score of 41), followed by HSP90AA1 (37), MAPK1 (36), RHOA (28), EGFR (27), AKT1 (27), PTPN11 (27), ESR1 (26), RXRA (26), HRAS (26), MAPK14 (24), MAPK8 (22), HDAC1 (22), VEGFA (21), and JAK2 (21).

3.3. GO and KEGG Enrichment Analyses

In the GO analysis (minimum overlap = 3, , and minimum enrichment = 1.5), there were 260 BPs, 120 MFs, and 98 CCs. The top 20 BPs, MFs, and CCs (ranked by −log₁₀ ( value)) are shown in Figures 3(a)–3(c), respectively. The highest-ranked BP, MF, and CC were protein phosphorylation, protein kinase activity, and vesicle lumen, respectively.

(a)

(b)

(c)

(d)

In the KEGG analysis, 157 pathways were predicted. The top 20 pathways (ranked by −log₁₀ ( value)) are shown in Figure 3(d). Among the top 20, several apparently unrelated pathways were disregarded (e.g., pathways in cancer), and the mitogen-activated protein kinase (MAPK) signaling pathway mostly attracted our interest.

3.4. Molecular Docking Analysis

As the MAPK signaling pathway may be key, the docking of orientin with the following three MAPK-related proteins was investigated: MAPK1 (PDB ID: 7E73), MAPK8 (PDB ID: 3VUM), and MAPK14 (PDB ID: 3FLZ). As shown in Figures 4(a)–4(c), orientin exhibited tight binding with all three target proteins, with >1 hydrogen bond, suggesting that orientin can strongly associate with these proteins. The binding energies were low, at −8.1, −5.1, and −8.2 for MAPK1, MAPK8, and MAPK14, indicating stable compound-protein binding (threshold: <−5 kcal/mol) [55].

(a)

(b)

(c)

(d)

(e)

(f)

Figure 4

The molecular docking results. (a) The locally enlarged picture of orientin bonding to 7E73 (MAPK1). (b) The two-dimensional picture of orientin bonding to 7E73 (MAPK1). (c) The locally enlarged picture of orientin bonding to 3VUM (MAPK8). (d) The two-dimensional picture of orientin bonding to 3VUM (MAPK8). (e) The locally enlarged picture of orientin bonding to 3FLZ (MAPK14). (f) The two-dimensional picture of orientin bonding to 3FLZ (MAPK14). Amino acids are shown in red and hydrogen bond distances are shown in yellow dashed lines (unit: Å).

3.5. Effect of Orientin on Mechanical and Thermal Pain Thresholds in Adult Mice

As shown in Figures 5(a) and 5(b), at P7, PWMT and TWL were significantly decreased in the model group compared to the control group, indicating immediate hyperalgesia in neonatal mice. In addition, PMWT was increased in two orientin groups (14 and 21 mg/kg) and TWL in all three orientin groups compared to the model group. PMWT and TWL were not different in the sham group compared to the control group, indicating that gentle touch did not elicit neonatal pain.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

Figure 5

The experiment validation of pain. (a) The PWMT of mice at day 7 (P7). (b) The TWL at day 7 (P7). (c) The PWMT at week 8 (W8). (d) The TWL at week 8 (W8). The experiment validation of cognition at week 8 (W8). (e) The escape latency in the spatial learning phase (s). (f) Numbers of crossings of the platform. (g) The swimming length in the target quadrant (cm). (h) The time spent in the target quadrant (s). (i) The swimming speed (s). (j) The swimming track diagram during the probe test on day 6 (the probe test phase). The red dot is the starting point, the blue dot is the ending point, and the original platform position is a red circle in quadrant 2. Significant differences between model groups and other groups are indicated as , , and .

As shown in Figures 5(c) and 5(d), at W8 (after reinjury), PWMT and TWL were significantly decreased in the model group compared to the control group, indicating long-term hyperalgesia in adult mice that experienced repeated procedural neonatal pain. PMWT was increased in all three orientin groups and TWL in two orientin groups (14 and 21 mg/kg) compared to the model group.

3.6. Effect of Orientin on Cognition in Adulthood

As shown in Figure 5(e), in the spatial learning test, the escape latency was not significantly different in the model group compared to the other groups on day 1. However, on days 3–5, the escape latencies were significantly increased in the model group compared to the control group and significantly reduced in the orientin groups compared to the model group (21 mg/kg groups on days 3–5, 14 mg/kg groups on days 4–5, and 7 mg/kg group on day 5). During the probe test on day 6, platform crossings decreased and the time spent on the target quadrant decreased in the model group compared to the control group. However, in the orientin groups compared to the model group, the number of platform crossings increased (7 and 21 mg/kg groups) (Figure 5(f)) and the swimming length and time spent on the target quadrant increased (14 and 21 mg/kg groups) (Figures 5(g) and 5(h)). There were no significant differences between the control and sham groups. Swimming speeds are shown in Figure 5(i) while representative traces are shown in Figure 5(j).

3.7. In Vivo Validation of Mechanism of Action

As shown in Figure 6(a), the pMAPK1 (p-ERK) protein levels in the hippocampus (quantification of CA1 region in Figure 6(b) and CA3 region in Figure 6(c)) were increased in the model group compared to the control group and decreased in the orientin group compared to the model group. The gene expression of MAPK1 showed a similar tendency in Figure 6(d). The pMAPK1 protein levels in the spinal dorsal horn exhibited similar patterns, as shown in Figures 6(e) and 6(f).

Figure 6

The intrinsic mechanical experiment validation. (a) The pMAPK1 (p-ERK) levels in the hippocampus of the brain and quantification in the CA1 region (b) and quantification in the CA3 region (c). Inner scale bar at top left corner = 100 μm. (d) The MAPK1 gene expression in the brain. The pMAPK1 levels in the spinal dorsal horn (e) and quantification (f). Inner scale bar at top left corner = 20 μm. Significant difference between model groups and other groups were indicated as , , and .

4. Discussion

Although researchers have found that orientin has multiple pharmacologic effects, this is the first study to show that orientin inhibited the long-term hyperalgesia and cognitive impairment elicited by repeated procedural neonatal pain. Network pharmacology and molecular docking analysis predicted that the MAPK signaling pathway may be involved. In particular, the pMAPK1 levels in the central nervous system of mice play crucial roles in orientin’s effect.

The behavioral changes in adult mice that were exposed to repeated procedural pain as neonates have attracted many pediatric researchers’ interest. Neonatal pain elicits a range of immediate and long-term adverse effects in neonates and adults. Clinical observations revealed the mechanical hyperalgesia and conditioning of the pain response [56]. An increase in inflammatory cytokines such as interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) was found in rats with repeated procedural neonatal pain; these cytokines participate in central sensitization and hyperalgesia development and maintenance [57]. MAPK is tightly linked with neuroinflammation and cytokine production [58] and is involved in a positive feedback mechanism involving excessive spinal dynorphin expression after peripheral noxious stimulation [59, 60]. Inhibition of MAPK in a neuropathic pain model downregulated the excessive production of cytokines in the spinal dorsal horn [61]. In our study, the phosphorylation of MAPK1 in the dorsal horn likely played crucial roles in orientin’s effect on neonatal pain immediately and in the long-term in adults.

Another important adverse effect of repeated procedural neonatal pain is cognitive impairment. Inflammatory pain in the early life of rats elicits long-term deficits in the hippocampal-dependent spatial memory [62]. A well-acknowledged mechanism of neonatal pain-induced adult changes is the activation of the hypothalamic-pituitary-adrenal (HPA) axis and related changes in the hippocampus [63, 64]. In premature infants in neonatal intensive care units, the frequency of skin incision/puncturing procedures is closely related to high cortisol in later life [65]. Another report on rats revealed that neonatal pain elicited immune activation involving both spinal cord neurons and the HPA axis [66]. The HPA axis is linked to the MAPK signaling pathway, and this pathway is a key pathway regulated in the hippocampus in both acute and chronic stress [67]. Intracerebroventricular injection of corticotropin-releasing hormone in mice increased pMAPK1 in hippocampal CA1-CA3 areas [68], while it reduced pMAPK (P38 and ERK) levels in rats which improved cognitive impairment [69]. In the present study, inhibition of MAPK1 in the hippocampus likely played a role in orientin’s preventative effect regarding cognitive impairment.

This study has several strengths and limitations. The primary strength is that we reported a new application, i.e., pediatric pain management, of a well-known and well-tested agent. Animal research on orientin has been conducted for over 2 decades [70]. Multiple studies indicate that orientin is a relatively safe compound [23, 71]. Our study suggested another natural product for neonatal pain, although there is a huge gap from preclinical to clinical. Another major finding is that the MAPK signaling pathway is not only activated in the spinal dorsal horn after repeated procedural pain in neonatal mice but it is also activated in the hippocampus, which has not been reported in previous studies. The phosphorylation of MAPK1 in the hippocampus has been suggested to be responsible for depression, cognitive decline, and other symptoms in adulthood in animal models of repeated procedural neonatal pain [59]. In addition, we reported the link between orientin and MAPK1 in a new organ, i.e., the brain. Previous experiments involving extracts containing orientin revealed that orientin regulated the MAPK signaling pathway [72, 73], and other studies suggested that SRC and MAPK play a crucial role in orientin’s antiapoptosis ability [74] and p38 MAPK was involved in orientin’s antioxidative stress effect [75]. However, most of these results came from in vitro models [72–74]. The current study revealed that orientin regulated MAPK1 activity in the brain. Supplementation with orientin-enriched food, such as fruit, may be an alternative strategy for pain management in premature neonates.

In contrast, the primary study limitation is the lack of an agonist/inhibitor of MAPK signaling used in animal experiments. Orientin is a highly water-soluble flavone and can exert effects on the brain [76, 77]. In contrast, most agonists for use in the brain require intracerebroventricular injection, and although we tried several approaches for intracerebroventricular injection in newborn pups in preliminary experiments, all attempts failed. Therefore, an agonist/inhibitor of MAPK signaling pathway was not used in animal experiments so there was a lack of validation of the role of MAPKs.

Some aspects which should be paid more attention to in future studies are as follows. First, there are many types of chronic pain in pediatric patients, for example, postoperative pain, abdominal pain, repetitive operational pain, nociceptive pain, and low back pain [78, 79]. However, the mechanisms of chronic pain are commonly similar, mainly caused by the complex interaction between primary afferent nerves, dorsal horn neurons, spinal glia, and brain [78]. Central sensitization, several signaling pathways, and neuroinflammatory genes contributed to the pain [80]. Among them, nuclear factor kappa B (NF-κΒ), MAPK, and inflammasome NOD-like receptor (NLR family) pyrin domain containing 3 NLRP3 play important roles in neuroinflammation and pain [81]. Flavonoids are natural compounds, found in fruits, vegetables, and various dietary sources. Flavonoids have been widely used for their analgesic effect due to their anti-inflammatory and antioxidant abilities. For example, quercetin modulated the MAPK, NF-κB, and NLRP3 to alleviate the inflammatory pain, neuropathic pain, and cancer pain [82]. Orientin can modulate the MAPK and NF-κB [24], therefore it can be used for other chronic pain treatments in pediatric patients. Second, there is a huge gap between preclinical and clinical experiments. Current studies on orientin were animal studies [83, 84], therefore the pain alleviation effect and side effect on humans are unknown. Fortunately, the structure of orientin is similar to luteolin [85], while luteolin has been tested in many clinical trials. Luteolin is effective in pain inhibition [81], with above 5,000 mg/kg LD50 values in rats [86], and safe in pediatric patients [87]. The orientin is C-glycoside while luteolin is aglycone [88]. Compared with aglycone, a glycoside is commonly a more suitable drug because it can improve stability, increase water solubility, reduce toxicity, and most importantly, enhance the specific targeting properties of drugs [88]. Therefore, it can be predicted that orientin is an effective and relatively safe drug. Moreover, to mimic the gap, strict clinical trials on dose and the side effects are critical in the future. Third, orientin research studies may develop in the following directions. For preclinical research, current research studies on pain mediators and regulators were gradually enriched, and research studies on new pathways and mechanisms have increased. However, research on the mechanism of orientin in neonatal pain was limited. Therefore, it is necessary to expand the investigation on new mechanisms of orientin in neonatal pain. For clinical research, research on its effectiveness, safety, and drug metabolism, especially metabolism, in the central nervous system of newborns and infants will be critical.

5. Conclusion

Based on network pharmacology, molecular docking analysis, and experimental validation, this study revealed that orientin alleviated repeated procedural neonatal pain and improved the long-term cognitive deficit. The MAPK signaling pathway plays a crucial role in the effect of orientin. Molecular docking analysis predicted that orientin can bind tightly to the target MAPK proteins. This study provided new insights into the potential application of a natural flavonoid for neonatal pain treatment.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare there are no conflicts of interest.

Authors’ Contributions

All authors made substantial contribution to this study and approved it for publication. Among them, Xing-Jing Luo designed it. Hai-E Liu and Kun Liu performed the pharmacology analysis and molecular docking. Dong-Dong Guo and Hai-yan Huang performed the animal experiments. The data were analyzed by Dong-Dong Guo and Hai-yan Huang. Dong-dong Guo wrote the manuscript while Xing-Jing Luo critically revised it. Dong-Dong Guo and Hai-Yan Huang equally contributed to this study.

Acknowledgments

This work was financially supported by the Natural and Science Fund of the Tibet Autonomous Region (XZ2019ZR-ZY48(Z)).

References

D. P. Barker and N. Rutter, “Exposure to invasive procedures in neonatal intensive care unit admissions,” Archives of Disease in Childhood: Fetal and Neonatal Edition, vol. 72, no. 1, pp. F47–F48, 1995.
View at: Publisher Site | Google Scholar
S. H. Simons, M. van Dijk, K. S. Anand, D. Roofthooft, R. A. van Lingen, and D. Tibboel, “Do we still hurt newborn babies? A prospective study of procedural pain and analgesia in neonates,” Archives of Pediatrics and Adolescent Medicine, vol. 157, no. 11, pp. 1058–1064, 2003.
View at: Publisher Site | Google Scholar
R. Carbajal, A. Rousset, C. Danan et al., “Epidemiology and treatment of painful procedures in neonates in intensive care units,” The Journal of the American Medical Associati, vol. 300, no. 1, pp. 60–70, 2008.
View at: Publisher Site | Google Scholar
R. E. Grunau, “Neonatal pain in very preterm infants: long-term effects on brain, neurodevelopment and pain reactivity,” Rambam Maimonides Medical Journal, vol. 4, p. 25, 2013.
View at: Publisher Site | Google Scholar
M. Ranger and R. E. Grunau, “How do babies feel pain?” Elife, vol. 4, p. 7552, 2015.
View at: Publisher Site | Google Scholar
O. Finnström and J. Schollin, “Newborn infants do feel pain! Technique and environment in connection with specimen collection can be improved,” Lakartidningen, vol. 95, no. 50, pp. 5718–5720, 1998.
View at: Google Scholar
M. Perry, Z. Tan, J. Chen, T. Weidig, W. Xu, and X. S. Cong, “Neonatal pain: perceptions and current practice,” Critical Care Nursing Clinics of North America, vol. 30, no. 4, pp. 549–561, 2018.
View at: Publisher Site | Google Scholar
M. Ranger, S. Tremblay, C. M. Y. Chau, L. Holsti, R. E. Grunau, and D. Goldowitz, “Adverse behavioral changes in adult mice following neonatal repeated exposure to pain and sucrose,” Frontiers in Psychology, vol. 9, p. 2394, 2018.
View at: Publisher Site | Google Scholar
N. J. van den Hoogen, D. Tibboel, W. M. Honig, D. Hermes, J. Patijn, and E. A. Joosten, “Neonatal paracetamol treatment reduces long-term nociceptive behaviour after neonatal procedural pain in rats,” European Journal of Pain, vol. 20, no. 8, pp. 1309–1318, 2016.
View at: Publisher Site | Google Scholar
K. Y. Lam, A. P. Ling, R. Y. Koh, Y. P. Wong, and Y. H. Say, “A review on medicinal properties of orientin,” Advances in Pharmacological Sciences, vol. 2016, Article ID 4104595, 9 pages, 2016.
View at: Publisher Site | Google Scholar
J. Tian, C. Qu, and J. Yan, “Separation and purification of orientin and vitexin in trollius chinensis bunge by PHPLC,” Chinese Traditional Patent Medicine, vol. 33, pp. 655–658, 2011.
View at: Google Scholar
S. Ye, F. Pan, L. Yao et al., “Isolation, characterization of bamboo leaf flavonoids by size exclusion chromatography and their antioxidant properties,” Chemistry and Biodiversity, vol. 19, no. 9, Article ID 202200506, 2022.
View at: Publisher Site | Google Scholar
S. Perveen, A. M. El-Shafae, A. Al-Taweel et al., “Antioxidant and urease inhibitory C-glycosylflavonoids from Celtis africana,” Journal of Asian Natural Products Research, vol. 13, no. 9, pp. 799–804, 2011.
View at: Publisher Site | Google Scholar
A. C. Pilon, R. L. Carneiro, F. Carnevale Neto, V. da S Bolzani, and I. Castro-Gamboa, “Interval multivariate curve resolution in the dereplication of HPLC-DAD data from Jatropha gossypifolia,” Phytochemical Analysis, vol. 24, no. 4, pp. 401–406, 2013.
View at: Publisher Site | Google Scholar
S. J. Kim, T. H. Pham, Y. Bak, H. W. Ryu, S. R. Oh, and D. Y. Yoon, “Orientin inhibits invasion by suppressing MMP-9 and IL-8 expression via the PKCα/ERK/AP-1/STAT3-mediated signaling pathways in TPA-treated MCF-7 breast cancer cells,” Phytomedicine, vol. 50, pp. 35–42, 2018.
View at: Publisher Site | Google Scholar
Y. L. Li, S. C. Ma, Y. T. Yang, S. M. Ye, and P. P. But, “Antiviral activities of flavonoids and organic acid from Trollius chinensis Bunge,” Journal of Ethnopharmacology, vol. 79, no. 3, pp. 365–368, 2002.
View at: Publisher Site | Google Scholar
F. An, S. Wang, D. Yuan, Y. Gong, and S. Wang, “Attenuation of oxidative stress of erythrocytes by plant-derived flavonoids, orientin and luteolin,” Evidence-based Complementary and Alternative Medicine, vol. 2016, Article ID 3401269, 8 pages, 2016.
View at: Publisher Site | Google Scholar
Q. Xiao, Z. Qu, Y. Zhao, L. Yang, and P. Gao, “Orientin ameliorates LPS-induced inflammatory responses through the inhibitory of the NF-κB pathway and NLRP3 inflammasome,” Evidence-based Complementary and Alternative Medicine, vol. 2017, Article ID 2495496, 8 pages, 2017.
View at: Publisher Site | Google Scholar
F. U. Xiao-Chun, Z. X. Huang, Y. W. Cai, and Q. H. Yang, “Protective effects of orientin on experimental myocardial infarction in dogs,” Herald of Medicine, vol. 25, pp. 621–623, 2006.
View at: Google Scholar
P. Uma Devi, A. Ganasoundari, B. Vrinda, K. K. Srinivasan, and M. K. Unnikrishnan, “Radiation protection by the ocimum flavonoids orientin and vicenin: mechanisms of action,” Radiation Research, vol. 154, no. 4, pp. 455–460, 2000.
View at: Publisher Site | Google Scholar
T. Tian, J. Zeng, G. Zhao, W. Zhao, S. Gao, and L. Liu, “Neuroprotective effects of orientin on oxygen-glucose deprivation/reperfusion-induced cell injury in primary culture of rat cortical neurons,” Experimental Biology and Medicine, vol. 243, no. 1, pp. 78–86, 2018.
View at: Publisher Site | Google Scholar
X. Wang, F. An, S. Wang, Z. An, and S. Wang, “Orientin attenuates cerebral ischemia/reperfusion injury in rat model through the AQP-4 and TLR4/NF-κB/TNF-α signaling pathway,” Journal of Stroke and Cerebrovascular Diseases, vol. 26, no. 10, pp. 2199–2214, 2017.
View at: Publisher Site | Google Scholar
Z. L. Kong, K. Che, J. X. Hu et al., “Orientin protects podocytes from high glucose induced apoptosis through mitophagy,” Chemistry and Biodiversity, vol. 17, no. 3, Article ID 1900647, 2020.
View at: Publisher Site | Google Scholar
D. Guo, X. Hu, H. Zhang, C. Lu, G. Cui, and X. Luo, “Orientin and neuropathic pain in rats with spinal nerve ligation,” International Immunopharmacology, vol. 58, pp. 72–79, 2018.
View at: Publisher Site | Google Scholar
F. Xu, W. Cai, T. Ma et al., “Traditional uses, phytochemistry, pharmacology, quality control, industrial application, pharmacokinetics and network pharmacology of pogostemon cablin: a comprehensive review,” American Journal of Chinese Medicine, vol. 50, no. 3, pp. 691–721, 2022.
View at: Publisher Site | Google Scholar
A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008.
View at: Publisher Site | Google Scholar
L. Pinzi and G. Rastelli, “Molecular docking: shifting paradigms in drug discovery,” International Journal of Molecular Sciences, vol. 20, no. 18, p. 4331, 2019.
View at: Publisher Site | Google Scholar
M. Huang, S. Yu, Q. Shao et al., “Comprehensive profiling of Lingzhihuang capsule by liquid chromatography coupled with mass spectrometry-based molecular networking and target prediction,” Acupuncture and Herbal Medicine, vol. 2, no. 1, pp. 58–67, 2022.
View at: Publisher Site | Google Scholar
Y. Fan, W. Liu, Y. Jin et al., “Integrated molecular docking with network pharmacology to reveal the molecular mechanism of simiao powder in the treatment of acute gouty arthritis,” Evidence-based Complementary and Alternative Medicine, vol. 2021, Article ID 5570968, 15 pages, 2021.
View at: Publisher Site | Google Scholar
J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014.
View at: Publisher Site | Google Scholar
A. Daina, O. Michielin, and V. Zoete, “SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules,” Nucleic Acids Research, vol. 47, no. 1, pp. W357–w364, 2019.
View at: Publisher Site | Google Scholar
J. Nickel, B. O. Gohlke, J. Erehman et al., “SuperPred: update on drug classification and target prediction,” Nucleic Acids Research, vol. 42, no. 1, pp. W26–W31, 2014.
View at: Publisher Site | Google Scholar
M. Rebhan, V. Chalifa-Caspi, J. Prilusky, and D. Lancet, “GeneCards: integrating information about genes, proteins and diseases,” Trends in Genetics, vol. 13, no. 4, p. 163, 1997.
View at: Publisher Site | Google Scholar
J. Piñero, À. Bravo, N. Queralt-Rosinach et al., “DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants,” Nucleic Acids Research, vol. 45, no. 1, pp. D833–d839, 2017.
View at: Publisher Site | Google Scholar
D. S. Wishart, Y. D. Feunang, A. C. Guo et al., “DrugBank 5.0: a major update to the DrugBank database for 2018,” Nucleic Acids Research, vol. 46, no. 1, pp. d1074–d1082, 2018.
View at: Publisher Site | Google Scholar
T. UniProt Consortium, “UniProt: the universal protein knowledgebase,” Nucleic Acids Research, vol. 46, no. 5, p. 2699, 2018.
View at: Publisher Site | Google Scholar
J. Oliveros, “Venny,” An interactive tool for comparing lists with Venn’s diagrams, Wuhan, China, 2016.
D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” Nucleic Acids Research, vol. 47, no. 1, pp. D607–d613, 2019.
View at: Publisher Site | Google Scholar
L. Xu, J. Zhang, Y. Wang, Z. Zhang, F. Wang, and X. Tang, “Uncovering the mechanism of Ge-Gen-Qin-Lian decoction for treating ulcerative colitis based on network pharmacology and molecular docking verification,” Bioscience Reports, vol. 41, no. 2, Article ID 20203565, 2021.
View at: Publisher Site | Google Scholar
P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.
View at: Publisher Site | Google Scholar
C. H. Chin, S. H. Chen, H. H. Wu, C. W. Ho, M. T. Ko, and C. Y. Lin, “cytoHubba: identifying hub objects and sub-networks from complex interactome,” Bhubaneswar Municipal Corporation Systems Biology, vol. 8, no. 4, p. 11, 2014.
View at: Publisher Site | Google Scholar
Y. Zhou, B. Zhou, L. Pache et al., “Metascape provides a biologist-oriented resource for the analysis of systems-level datasets,” Nature Communications, vol. 10, no. 1, p. 1523, 2019.
View at: Publisher Site | Google Scholar
O. Trott and A. J. Olson, “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” Journal of Computational Chemistry, vol. 31, no. 2, pp. 455–461, 2010.
View at: Publisher Site | Google Scholar
B. H. M. Mooers, “Shortcuts for faster image creation in PyMOL,” Protein Science, vol. 29, no. 1, pp. 268–276, 2020.
View at: Publisher Site | Google Scholar
S. M. Walker, “Neonatal pain,” Pediatric Anesthesia, vol. 24, no. 1, pp. 39–48, 2014.
View at: Publisher Site | Google Scholar
L. Knaepen, J. Patijn, D. Tibboel, and E. A. Joosten, “Sex differences in inflammatory mechanical hypersensitivity in later life of rats exposed to repetitive needle pricking as neonates,” Neuroscience Letters, vol. 516, no. 2, pp. 285–289, 2012.
View at: Publisher Site | Google Scholar
L. Dührsen, S. H. Simons, M. Dzietko et al., “Effects of repetitive exposure to pain and morphine treatment on the neonatal rat brain,” Neonatology, vol. 103, no. 1, pp. 35–43, 2013.
View at: Publisher Site | Google Scholar
N. J. van den Hoogen, T. J. de Geus, J. Patijn, D. Tibboel, and E. A. Joosten, “Methadone effectively attenuates acute and long-term consequences of neonatal repetitive procedural pain in a rat model,” Pediatric Research, vol. 89, no. 7, pp. 1681–1686, 2021.
View at: Publisher Site | Google Scholar
S. J. Dang, W. B. Wei, R. L. Li, C. X. Song, and J. Xu, “Z-guggulsterone relieves neuropathic pain by inhibiting the expression of astrocytes and proinflammatory cytokines in the spinal dorsal horn,” Journal of Pain Research, vol. 15, pp. 1315–1324, 2022.
View at: Publisher Site | Google Scholar
J. J. Xu, P. Gao, Y. Wu et al., “G protein-coupled estrogen receptor in the rostral ventromedial medulla contributes to the chronification of postoperative pain,” Central nervous system Neuroscience and Therapeutics, vol. 27, no. 11, pp. 1313–1326, 2021.
View at: Publisher Site | Google Scholar
Y. Hatanaka, T. Umeda, K. Shigemori, T. Takeuchi, Y. Nagai, and T. Tomiyama, “C9orf72 hexanucleotide repeat expansion-related neuropathology is attenuated by nasal rifampicin in mice,” Biomedicines, vol. 10, no. 5, p. 1080, 2022.
View at: Publisher Site | Google Scholar
W. Li, C. Ke, C. Yang et al., “LncRNA DICER1-AS1 promotes colorectal cancer progression by activating the MAPK/ERK signaling pathway through sponging miR-650,” Cancer Medicine, vol. 12, no. 7, pp. 8351–8366, 2023.
View at: Publisher Site | Google Scholar
M. Marcatti, A. Fracassi, M. Montalbano et al., “Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer’s disease,” Cellular and Molecular Life Sciences, vol. 79, no. 4, p. 222, 2022.
View at: Publisher Site | Google Scholar
O. J. Gannon, L. S. Robison, A. E. Salinero et al., “High-fat diet exacerbates cognitive decline in mouse models of Alzheimer’s disease and mixed dementia in a sex-dependent manner,” Journal of Neuroinflammation, vol. 19, no. 1, p. 110, 2022.
View at: Publisher Site | Google Scholar
J. Zhang, Y. Zhou, and Z. Ma, “Multi-target mechanism of Tripteryguim wilfordii Hook for treatment of ankylosing spondylitis based on network pharmacology and molecular docking,” Annals of Medicine, vol. 53, no. 1, pp. 1091–1099, 2021.
View at: Publisher Site | Google Scholar
M. Fitzgerald, C. Millard, and N. McIntosh, “Cutaneous hypersensitivity following peripheral tissue damage in newborn infants and its reversal with topical anaesthesia,” Pain, vol. 39, no. 1, pp. 31–36, 1989.
View at: Publisher Site | Google Scholar
J. Zhang, J. Yin, X. Chen et al., “Down-regulation of miR-140-3p can alleviate neonatal repetitive pain in rats via inhibiting TGF-β3,” Biochemical and Biophysical Research Communications, vol. 515, no. 4, pp. 627–635, 2019.
View at: Publisher Site | Google Scholar
S. Vishwakarma, S. Singh, and T. G. Singh, “Pharmacological modulation of cytokines correlating neuroinflammatory cascades in epileptogenesis,” Molecular Biology Reports, vol. 49, no. 2, pp. 1437–1452, 2022.
View at: Publisher Site | Google Scholar
J. Y. Lin, Y. C. Cheng, J. Y. Chen et al., “Increased spinal prodynorphin gene expression in reinflammation-associated hyperalgesia after neonatal inflammatory insult,” Bhubaneswar Municipal Corporation Neuroscience, vol. 11, no. 1, p. 139, 2010.
View at: Publisher Site | Google Scholar
R. R. Ji, K. Befort, G. J. Brenner, and C. J. Woolf, “ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity,” Journal of Neuroscience, vol. 22, no. 2, pp. 478–485, 2002.
View at: Publisher Site | Google Scholar
L. Tan, Y. Hu, X. Zhang et al., “Corydecumine G inhibits microglia activation via MAPK pathway in a rat model of neuropathic pain,” Journal of Chemical Neuroanatomy, vol. 124, Article ID 102124, 2022.
View at: Publisher Site | Google Scholar
Y. O. Henderson, N. C. Victoria, K. Inoue, A. Z. Murphy, and M. B. Parent, “Early life inflammatory pain induces long-lasting deficits in hippocampal-dependent spatial memory in male and female rats,” Neurobiology of Learning and Memory, vol. 118, pp. 30–41, 2015.
View at: Publisher Site | Google Scholar
M. Chen, D. Xia, C. Min et al., “Neonatal repetitive pain in rats leads to impaired spatial learning and dysregulated hypothalamic-pituitary-adrenal axis function in later life,” Scientific Reports, vol. 6, no. 1, Article ID 39159, 2016.
View at: Publisher Site | Google Scholar
I. P. Butkevich, V. A. Mikhailenko, E. A. Vershinina, and G. A. Barr, “The long-term effects of neonatal inflammatory pain on cognitive function and stress hormones depend on the heterogeneity of the adolescent period of development in male and female rats,” Frontiers in Behavioral Neuroscience, vol. 15, Article ID 691578, 2021.
View at: Publisher Site | Google Scholar
R. E. Grunau, D. W. Haley, M. F. Whitfield, J. Weinberg, W. Yu, and P. Thiessen, “Altered basal cortisol levels at 3, 6, 8 and 18 months in infants born at extremely low gestational age,” The Journal of Pediatrics, vol. 150, no. 2, pp. 151–156, 2007.
View at: Publisher Site | Google Scholar
I. Zouikr, M. A. Tadros, J. Barouei et al., “Altered nociceptive, endocrine, and dorsal horn neuron responses in rats following a neonatal immune challenge,” Psychoneuroendocrinology, vol. 41, pp. 1–12, 2014.
View at: Publisher Site | Google Scholar
C. L. Ferland, E. P. Harris, M. Lam, and L. A. Schrader, “Facilitation of the HPA axis to a novel acute stress following chronic stress exposure modulates histone acetylation and the ERK/MAPK pathway in the dentate gyrus of male rats,” Endocrinology, vol. 155, no. 8, pp. 2942–2952, 2014.
View at: Publisher Site | Google Scholar
J. J. Bonfiglio, C. Inda, D. Refojo, F. Holsboer, E. Arzt, and S. Silberstein, “The corticotropin-releasing hormone network and the hypothalamic-pituitary-adrenal axis: molecular and cellular mechanisms involved,” Neuroendocrinology, vol. 94, no. 1, pp. 12–20, 2011.
View at: Publisher Site | Google Scholar
H. M. A. Khalil, H. A. Eliwa, R. A. El-Shiekh et al., “Ashwagandha (Withania somnifera) root extract attenuates hepatic and cognitive deficits in thioacetamide-induced rat model of hepatic encephalopathy via induction of Nrf2/HO-1 and mitigation of NF-κB/MAPK signaling pathways,” Journal of Ethnopharmacology, vol. 277, Article ID 114141, 2021.
View at: Publisher Site | Google Scholar
P. U. Devi, A. Ganasoundari, B. S. Rao, and K. K. Srinivasan, “In vivo radioprotection by ocimum flavonoids: survival of mice,” Radiation Research, vol. 151, no. 1, pp. 74–78, 1999.
View at: Publisher Site | Google Scholar
V. Nayak and P. U. Devi, “Protection of mouse bone marrow against radiation-induced chromosome damage and stem cell death by the ocimum flavonoids orientin and vicenin,” Radiation Research, vol. 163, no. 2, pp. 165–171, 2005.
View at: Publisher Site | Google Scholar
Y. H. Kim, T. W. Oh, E. Park et al., “Anti-inflammatory and anti-apoptotic effects of acer palmatum thumb. Extract, KIOM-2015ew, in a hyperosmolar-stress-induced in vitro dry eye model,” Nutrients, vol. 10, no. 3, p. 282, 2018.
View at: Publisher Site | Google Scholar
E. J. Nam, G. Yoo, J. Y. Lee et al., “Glycosyl flavones from Humulus japonicus suppress MMP-1 production via decreasing oxidative stress in UVB irradiated human dermal fibroblasts,” Biochemistry & Molecular Biology Report, vol. 53, no. 7, pp. 379–384, 2020.
View at: Publisher Site | Google Scholar
S. Qi, Z. Feng, Q. Li, Z. Qi, and Y. Zhang, “Inhibition of ROS-mediated activation Src-MAPK/AKT signaling by orientin alleviates H(2)O(2)-induced apoptosis in PC12 cells,” Drug Design, Development and Therapy, vol. 12, pp. 3973–3984, 2018.
View at: Publisher Site | Google Scholar
F. Li, X. Liao, L. Jiang, J. Zhao, S. Wu, and J. Ming, “Orientin attenuated d-GalN/LPS-induced liver injury through the inhibition of oxidative stress via nrf2/keap1 pathway,” Journal of Agricultural and Food Chemistry, vol. 70, no. 26, pp. 7953–7967, 2022.
View at: Publisher Site | Google Scholar
Y. Liu, N. Lan, J. Ren et al., “Orientin improves depression-like behavior and BDNF in chronic stressed mice,” Molecular Nutrition and Food Research, vol. 59, no. 6, pp. 1130–1142, 2015.
View at: Publisher Site | Google Scholar
L. Yu, S. Wang, X. Chen et al., “Orientin alleviates cognitive deficits and oxidative stress in Aβ1-42-induced mouse model of Alzheimer’s disease,” Life Sciences, vol. 121, pp. 104–109, 2015.
View at: Publisher Site | Google Scholar
B. W. Landry, P. R. Fischer, S. W. Driscoll et al., “Managing chronic pain in children and adolescents: a clinical review,” Physical Medicine and Rehabilitation, vol. 7, no. 11, pp. S295–s315, 2015.
View at: Publisher Site | Google Scholar
T. E. Cooper, E. Fisher, A. L. Gray et al., “Opioids for chronic non-cancer pain in children and adolescents,” Cochrane Database of Systematic Reviews, vol. 7, Article ID 12538, 2017.
View at: Publisher Site | Google Scholar
G. Marchetti, A. Vittori, F. Ferrari et al., “Incidence of acute and chronic post-thoracotomy pain in pediatric patients,” Children, vol. 8, p. 642, 2021.
View at: Publisher Site | Google Scholar
F. Ntalouka and A. Tsirivakou, “Luteolin: a promising natural agent in management of pain in chronic conditions,” Front Pain Res (Lausanne), vol. 4, Article ID 1114428, 2023.
View at: Publisher Site | Google Scholar
A. J. Xu, Y. Q. Zhou, C. Liu et al., “The emerging role of quercetin in the treatment of chronic pain,” Current Neuropharmacology, vol. 20, no. 12, pp. 2346–2353, 2022.
View at: Publisher Site | Google Scholar
H. Dhakal, S. Lee, J. K. Choi, T. K. Kwon, D. Khang, and S. H. Kim, “Inhibitory effects of orientin in mast cell-mediated allergic inflammation,” Pharmacological Reports, vol. 72, no. 4, pp. 1002–1010, 2020.
View at: Publisher Site | Google Scholar
Z. Zhang, J. Wu, C. Teng et al., “Orientin downregulating oxidative stress-mediated endoplasmic reticulum stress and mitochondrial dysfunction through AMPK/SIRT1 pathway in rat nucleus pulposus cells in vitro and attenuated intervertebral disc degeneration in vivo,” Apoptosis, vol. 27, no. 11-12, pp. 1031–1048, 2022.
View at: Publisher Site | Google Scholar
S. Erşan, M. Müller, L. Reuter, R. Carle, and J. Müller-Maatsch, “Co-pigmentation of strawberry anthocyanins with phenolic compounds from rooibos,” Food Chemistry: Molecular Sciences, vol. 4, Article ID 100097, 2022.
View at: Publisher Site | Google Scholar
L. Dai, “The influence of luteolin on experimental inflammatory model in rat,” Acta Universitatis Medicinalis Anhui, vol. 20, pp. 1–3, 1985.
View at: Google Scholar
I. Tsilioni, A. Taliou, K. Francis, and T. C. Theoharides, “Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6,” Translational Psychiatry, vol. 5, no. 9, p. 647, 2015.
View at: Publisher Site | Google Scholar
L. Xie, Z. Deng, J. Zhang et al., “Comparison of flavonoid O-glycoside, C-glycoside and their aglycones on antioxidant capacity and metabolism during in vitro digestion and in vivo,” Foods, vol. 11, no. 6, p. 882, 2022.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Dong-Dong Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

153

Downloads

348

Citations